Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Avinger, Inc. (NASDAQ: AVGR).

Full DD Report for AVGR

You must become a subscriber to view this report.


Recent News from (NASDAQ: AVGR)

Avinger to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018
REDWOOD CITY, CA / ACCESSWIRE / November 7, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced its...
Source: ACCESSWIRE
Date: November, 07 2018 08:45
Avinger to Announce Third Quarter 2018 Financial Results on November 13, 2018
REDWOOD CITY, CA / ACCESSWIRE / November 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced tha...
Source: ACCESSWIRE
Date: November, 05 2018 07:30
Avinger Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
REDWOOD CITY, CA / ACCESSWIRE / November 1, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced t...
Source: ACCESSWIRE
Date: November, 01 2018 16:05
Avinger Announces Pricing of $10 Million Underwritten Public Offering
REDWOOD CITY, CA / ACCESSWIRE / October 30, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced t...
Source: ACCESSWIRE
Date: October, 30 2018 08:30
Avinger Announces Successful Treatment of 200th Patient with Next-Generation Pantheris Device
REDWOOD CITY, CA / ACCESSWIRE / September 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 35 sites globally have successfully treated over 200 patients with the next-generation Panth...
Source: ACCESSWIRE
Date: September, 05 2018 08:30
Avinger Announces 510(k) Filing of Pantheris Small Vessel Device
REDWOOD CITY, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the U.S Food & Drug Administration (FDA) for the Panth...
Source: GlobeNewswire
Date: August, 30 2018 08:30
Avinger receives new patent covering pantheris image-guided atherectomy system
Avinger (NASDAQ: AVGR ) announces the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy system. More news on: Avinger, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 09:00
Avinger Receives New Patent Covering Pantheris Image-Guided Atherectomy System
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy sy...
Source: GlobeNewswire
Date: August, 29 2018 08:30
Avinger Announces Participation in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that management of Avinger will present at the following investor conferences: Rodman & Renshaw 20t...
Source: GlobeNewswire
Date: August, 28 2018 08:30
Avinger Completes Enrollment in SCAN Clinical Study
REDWOOD CITY, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has completed enrollment in the SCAN clinical study, a post-market study comparing optical coherenc...
Source: GlobeNewswire
Date: August, 23 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-120.340.340.34480.32511,200,263
2018-12-110.340.3390.360.3251,253,312
2018-12-100.340.33980.340.32421,665,219
2018-12-070.35840.33320.35840.32312,332,080
2018-12-060.360.34640.3970.3312,713,969

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12166,811286,95158.1322Short
2018-12-11152,678271,40856.2541Short
2018-12-10255,087517,81549.2622Short
2018-12-07373,541697,20453.5770Short
2018-12-061,170,5302,264,50351.6904Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AVGR.


About Avinger, Inc. (NASDAQ: AVGR)

Logo for Avinger, Inc. (NASDAQ: AVGR)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AVGR)

      Amendment to a previously filed 8-K
      Filing Type: 8-K/AFiling Source: edgar
      Filing Date: May, 15 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Amendment to a previously filed 10-K
      Filing Type: 10-K/AFiling Source: edgar
      Filing Date: April, 26 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 21 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 19 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 23 2018

       

       


      Daily Technical Chart for (NASDAQ: AVGR)

      Daily Technical Chart for (NASDAQ: AVGR)


      Stay tuned for daily updates and more on (NASDAQ: AVGR)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AVGR)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVGR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AVGR and does not buy, sell, or trade any shares of AVGR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/